Monitoring breast cancer response to neoadjuvant chemotherapy with ultrasound signal statistics and integrated backscatter.
Hanna Piotrzkowska-WróblewskaKatarzyna Dobruch-SobczakZiemowit KlimondaPiotr KarwatKatarzyna Roszkowska-PurskaMagdalena GumowskaJerzy LitniewskiPublished in: PloS one (2019)
Quantitative ultrasound information can characterize the tumor's pathological response better and at an earlier stage of therapy than the assessment of the reduction of its dimensions. The introduction of statistical parameters of ultrasonic backscatter to monitor the effects of chemotherapy can increase the effectiveness of monitoring and contribute to a better personalization of NAC therapy.
Keyphrases
- neoadjuvant chemotherapy
- locally advanced
- magnetic resonance imaging
- systematic review
- lymph node
- randomized controlled trial
- sentinel lymph node
- squamous cell carcinoma
- transcription factor
- high resolution
- stem cells
- ultrasound guided
- healthcare
- computed tomography
- health information
- young adults
- early stage
- replacement therapy
- genome wide analysis
- chemotherapy induced
- breast cancer risk